Adaptive Stock Based Compensation from 2010 to 2025

ADPT Stock

USD 7.67 0.55 6.69%

Adaptive Biotechnologies Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation will likely drop to about 37.3 M in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2018-03-31

Previous Quarter

13.5 M

Current Value

12.8 M

Quarterly Volatility

5.1 M

Covid

Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 7.6 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 4.69, Dividend Yield of 0.0 or PTB Ratio of 4.57. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.

Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Latest Adaptive Biotechnologies' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Adaptive Biotechnologies Corp over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Adaptive Biotechnologies' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Adaptive Stock Based Compensation Regression Statistics

	Arithmetic Mean	22,353,390
	Geometric Mean	14,971,219
	Coefficient Of Variation	92.98
	Mean Deviation	17,898,612
	Median	11,149,000
	Standard Deviation	20,783,203
	Sample Variance	431.9T
	Range	55.9M
	R-Value	0.83
	Mean Square Error	140.7T
	R-Squared	0.70
	Significance	0.000059
	Slope	3,641,546
	Total Sum of Squares	6479.1T

Adaptive Stock Based Compensation History

	2025	37.3 M
	2024	53.6 M
	2023	62.9 M
	2022	55.5 M
	2021	43.3 M
	2020	24.8 M
	2019	13.1 M

Other Fundumenentals of Adaptive Biotechnologies

Stock Based Compensation To Revenue

Adaptive Biotechnologies Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Long Term Investments	Total Current Assets	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Capital Stock
Total Assets		0.99	0.93	0.95	0.49	-0.51	0.55	-0.3	0.47	-0.19	0.93	0.87	0.82	-0.87	0.99	0.77	0.96	0.85	-0.63	0.86	0.59	0.86
Total Stockholder Equity	0.99		0.98	0.98	0.57	-0.6	0.63	-0.33	0.57	-0.21	0.9	0.92	0.89	-0.93	1.0	0.77	0.94	0.82	-0.71	0.92	0.69	0.92
Net Tangible Assets	0.93	0.98		0.98	0.67	-0.71	0.73	-0.39	0.69	-0.27	0.85	0.96	0.96	-0.97	0.98	0.72	0.88	0.75	-0.8	0.98	0.79	0.97
Current Deferred Revenue	0.95	0.98	0.98		0.61	-0.69	0.68	-0.41	0.65	-0.29	0.82	0.95	0.93	-0.96	0.98	0.78	0.87	0.71	-0.78	0.96	0.78	0.96
Net Debt	0.49	0.57	0.67	0.61		-0.89	0.87	-0.5	0.86	-0.41	0.45	0.77	0.79	-0.74	0.57	0.22	0.47	0.28	-0.88	0.77	0.81	0.78
Retained Earnings	-0.51	-0.6	-0.71	-0.69	-0.89		-0.89	0.75	-0.92	0.67	-0.41	-0.85	-0.84	0.82	-0.6	-0.29	-0.45	-0.17	0.99	-0.83	-0.89	-0.85
Accounts Payable	0.55	0.63	0.73	0.68	0.87	-0.89		-0.47	0.98	-0.38	0.54	0.82	0.86	-0.78	0.63	0.15	0.56	0.4	-0.89	0.84	0.87	0.84
Long Term Debt	-0.3	-0.33	-0.39	-0.41	-0.5	0.75	-0.47		-0.49	0.99	-0.25	-0.61	-0.45	0.56	-0.33	-0.22	-0.26	0.11	0.74	-0.49	-0.42	-0.53
Net Receivables	0.47	0.57	0.69	0.65	0.86	-0.92	0.98	-0.49		-0.4	0.42	0.79	0.85	-0.75	0.57	0.14	0.44	0.27	-0.9	0.82	0.92	0.82
Good Will	-0.19	-0.21	-0.27	-0.29	-0.41	0.67	-0.38	0.99	-0.4		-0.14	-0.5	-0.32	0.45	-0.21	-0.14	-0.15	0.21	0.65	-0.37	-0.32	-0.41
Short Term Investments	0.93	0.9	0.85	0.82	0.45	-0.41	0.54	-0.25	0.42	-0.14		0.78	0.72	-0.76	0.9	0.52	0.99	0.93	-0.53	0.76	0.41	0.76
Long Term Debt Total	0.87	0.92	0.96	0.95	0.77	-0.85	0.82	-0.61	0.79	-0.5	0.78		0.96	-0.99	0.92	0.63	0.81	0.6	-0.92	0.98	0.83	0.99
Capital Surpluse	0.82	0.89	0.96	0.93	0.79	-0.84	0.86	-0.45	0.85	-0.32	0.72	0.96		-0.95	0.89	0.58	0.76	0.61	-0.9	0.99	0.92	0.99
Total Liab	-0.87	-0.93	-0.97	-0.96	-0.74	0.82	-0.78	0.56	-0.75	0.45	-0.76	-0.99	-0.95		-0.93	-0.7	-0.8	-0.59	0.89	-0.98	-0.82	-0.98
Net Invested Capital	0.99	1.0	0.98	0.98	0.57	-0.6	0.63	-0.33	0.57	-0.21	0.9	0.92	0.89	-0.93		0.77	0.94	0.82	-0.71	0.92	0.69	0.92
Long Term Investments	0.77	0.77	0.72	0.78	0.22	-0.29	0.15	-0.22	0.14	-0.14	0.52	0.63	0.58	-0.7	0.77		0.59	0.48	-0.4	0.62	0.44	0.62
Total Current Assets	0.96	0.94	0.88	0.87	0.47	-0.45	0.56	-0.26	0.44	-0.15	0.99	0.81	0.76	-0.8	0.94	0.59		0.92	-0.57	0.8	0.47	0.8
Net Working Capital	0.85	0.82	0.75	0.71	0.28	-0.17	0.4	0.11	0.27	0.21	0.93	0.6	0.61	-0.59	0.82	0.48	0.92		-0.29	0.64	0.3	0.62
Intangible Assets	-0.63	-0.71	-0.8	-0.78	-0.88	0.99	-0.89	0.74	-0.9	0.65	-0.53	-0.92	-0.9	0.89	-0.71	-0.4	-0.57	-0.29		-0.9	-0.89	-0.91
Common Stock	0.86	0.92	0.98	0.96	0.77	-0.83	0.84	-0.49	0.82	-0.37	0.76	0.98	0.99	-0.98	0.92	0.62	0.8	0.64	-0.9		0.88	1.0
Property Plant Equipment	0.59	0.69	0.79	0.78	0.81	-0.89	0.87	-0.42	0.92	-0.32	0.41	0.83	0.92	-0.82	0.69	0.44	0.47	0.3	-0.89	0.88		0.88
Capital Stock	0.86	0.92	0.97	0.96	0.78	-0.85	0.84	-0.53	0.82	-0.41	0.76	0.99	0.99	-0.98	0.92	0.62	0.8	0.62	-0.91	1.0	0.88

Click cells to compare fundamentals

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	53.6 M	37.3 M
Stock Based Compensation To Revenue	0.30	0.20

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptive Stock Based Compensation from 2010 to 2025

Latest Adaptive Biotechnologies' Stock Based Compensation Growth Pattern

Adaptive Stock Based Compensation Regression Statistics

Adaptive Stock Based Compensation History

Other Fundumenentals of Adaptive Biotechnologies

Adaptive Biotechnologies Stock Based Compensation component correlations

About Adaptive Biotechnologies Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Adaptive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY